Researchers at Tsukuba University have discovered that the increase in regulatory T (Treg) cells, which typically suppress ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to ...

The backlash against DEI gained steam during the 2024 presidential election but hit a fever pitch when Trump took office. The ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Regulatory T cells (TReg cells) are a special subset of T cells that prevent other immune cells from attacking the body’s own tissues and other harmless environmental materials, such as food and ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Proceeds to support key development milestones, including CMC advancement, initiation of a Phase I clinical trial in the first half of 2026, and strategic expansion of the leadership team ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...